Related Experiment Videos
The METHRO trials
Ali Hamaad1, Muzahir H Tayebjee, Gregory Y H Lip
1Haemostasis Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, B18 7QH, UK.
Expert Opinion on Investigational Drugs
|May 2, 2003
Summary
New anticoagulants melagatran and ximelagatran offer effective venous thromboembolism prophylaxis in orthopedic surgery patients. These oral agents provide a safer and more convenient alternative to traditional heparin injections and warfarin.
Area of Science:
- Medicine
- Pharmacology
- Surgery
Background:
- Venous thromboembolism (VTE) is a frequent and serious complication in hospitalized patients, especially after orthopedic surgery.
- Current prophylaxis involves low molecular weight heparins (LMWHs) and warfarin, but these have clinical drawbacks like painful injections and delayed anticoagulation.
- The METHRO trial investigated novel anticoagulants for VTE prevention in this high-risk group.
Purpose of the Study:
- To evaluate the efficacy and safety of a sequential anticoagulation strategy using melagatran and ximelagatran for VTE prophylaxis in orthopedic surgery.
- To compare this new regimen with established prophylactic methods.
Main Methods:
- The METHRO trial employed a sequential combination of subcutaneous melagatran followed by oral ximelagatran.
- This approach aimed to provide continuous anticoagulation for surgical VTE prophylaxis.
Main Results:
- Melagatran and ximelagatran demonstrated comparable efficacy and safety to LMWHs in preventing VTE after orthopedic surgery.
- These agents do not require dosage adjustments or therapeutic drug monitoring, simplifying clinical use.
Conclusions:
- The sequential use of melagatran and ximelagatran is an effective and safe alternative for VTE prophylaxis in orthopedic surgery.
- Ximelagatran shows potential to replace warfarin due to its favorable profile, including ease of use and no need for monitoring.